Cargando…

Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is characterized by the expression of the oncogenic kinase BCR-ABL. Although tyrosine kinase inhibitors (TKIs) against BCR-ABL represent the standard therapeutic option for CML, resistances to TKIs can be a serious problem. Thus, the search for novel therapeutic approa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romo-González, Marta, Moreno-Paz, Sara, García-Hernández, Violeta, Sánchez-Guijo, Fermín, Hernández-Hernández, Ángel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022995/ https://www.ncbi.nlm.nih.gov/pubmed/31952182 http://dx.doi.org/10.3390/antiox9010074

Ejemplares similares

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
por: Chen, Changyi, et al.
Publicado: (2016)

The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors
por: Liu, Ning, et al.
Publicado: (2021)

Evaluation of Neuronal Protective Effects of Xanthine Oxidoreductase Inhibitors on Severe Whole-brain Ischemia in Mouse Model and Analysis of Xanthine Oxidoreductase Activity in the Mouse Brain
por: SUZUKI, Go, et al.
Publicado: (2015)

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
por: García-Gutiérrez, Valentín, et al.
Publicado: (2020)

Pro-Aging Effects of Xanthine Oxidoreductase Products
por: Battelli, Maria Giulia, et al.
Publicado: (2020)

Xanthine oxidoreductase activity is correlated with hepatic steatosis
por: Yagi, Chisako, et al.
Publicado: (2022)

Discriminating Susceptibility of Xanthine Oxidoreductase Family to Metals
por: Steunou, Anne-Soisig, et al.
Publicado: (2023)

SHP1 and SHP2 inhibition enhances the pro-differentiative effect of phorbol esters: an alternative approach against acute myeloid leukemia
por: Pérez-Fernández, Alejandro, et al.
Publicado: (2019)

Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice
por: Nakamura, Takashi, et al.
Publicado: (2021)

Cyclin-Dependent Kinase Five Mediates Activation of Lung Xanthine Oxidoreductase in Response to Hypoxia
por: Kim, Bo S., et al.
Publicado: (2015)

Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase
por: Battelli, Maria Giulia, et al.
Publicado: (2018)

Xanthine oxidoreductase: One enzyme for multiple physiological tasks
por: Bortolotti, Massimo, et al.
Publicado: (2021)

Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
por: Mohanavelu, Prahathishree, et al.
Publicado: (2021)

Xanthine oxidoreductase gene polymorphisms are associated with high risk of sepsis and organ failure
por: Gao, Li, et al.
Publicado: (2023)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Hydrogen sulfide stimulates xanthine oxidoreductase conversion to nitrite reductase and formation of NO
por: Pardue, Sibile, et al.
Publicado: (2020)

Chemical Nature and Reaction Mechanisms of the Molybdenum Cofactor of Xanthine Oxidoreductase
por: Okamoto, Ken, et al.
Publicado: (2013)

Xanthine oxidoreductase in cancer: more than a differentiation marker
por: Battelli, Maria Giulia, et al.
Publicado: (2015)

Xanthine Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects
por: Battelli, Maria Giulia, et al.
Publicado: (2016)

Plasma Xanthine Oxidoreductase (XOR) Activity in Cardiovascular Disease Outpatients
por: Matsushita, Masato, et al.
Publicado: (2020)

Xanthine oxidoreductase: A leading actor in cardiovascular disease drama
por: Polito, Letizia, et al.
Publicado: (2021)

Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductase
por: Sekine, Mai, et al.
Publicado: (2023)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
por: Barak, Avital F., et al.
Publicado: (2011)

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018)

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
por: Langabeer, Stephen E., et al.
Publicado: (2020)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C., et al.
Publicado: (2020)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
por: Atallah, Ehab, et al.
Publicado: (2020)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Kim, Yundeok, et al.
Publicado: (2021)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia
por: Pokorny, Rebecca, et al.
Publicado: (2022)

Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2015)

Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
por: Stuckey, Ruth, et al.
Publicado: (2020)

Xanthine Oxidoreductase Reference Values in Platelet-Poor Plasma and Platelets in Healthy Volunteers
por: Cecerska-Heryć, Elżbieta, et al.
Publicado: (2015)

Evaluation of the Effectiveness of Xanthine Oxidoreductase Inhibitors on Haemodialysis Patients using a Marginal Structural Model
por: Ishii, Takeo, et al.
Publicado: (2017)

Diurnal Variations in Serum Uric Acid, Xanthine, and Xanthine Oxidoreductase Activity in Male Patients with Coronary Artery Disease
por: Shimizu, Megumi, et al.
Publicado: (2023)

Mutations Associated with Functional Disorder of Xanthine Oxidoreductase and Hereditary Xanthinuria in Humans
por: Ichida, Kimiyoshi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_p9j39u87n2f2s8lrgi07jfg5q9